Aclaris Therapeutics Inc (ACRS)

09:18 AM

Why Aclaris Therapeutics Inc. stock could rally in 2025Entry Point & Precise Trade Entry Recommendations - ulpravda.ru

09:18 AM

Jan 09, 2026

Will Aclaris Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Earnings & Daily Profit Focused Screening - ulpravda.ru

Jan 09, 2026

Jan 08, 2026

What valuation multiples suggest for Aclaris Therapeutics Inc. stockWeekly Stock Analysis & Long-Term Growth Plans - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Is Aclaris Therapeutics Inc. stock affected by interest rate hikesTrade Exit Report & Precise Swing Trade Alerts - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

How Aclaris Therapeutics Inc. stock benefits from strong dollar2025 Breakouts & Breakdowns & AI Powered Trade Plan Recommendations - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Market Recap: Can Aclaris Therapeutics Inc. (8AT) stock withstand sector downturnsJuly 2025 Pullbacks & Intraday High Probability Alerts - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Is Aclaris Therapeutics Inc. stock attractive for passive investorsBond Market & Free AI Powered Buy and Sell Recommendations - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Why analysts upgrade Aclaris Therapeutics Inc. stockMarket Sentiment Summary & Reliable Momentum Entry Alerts - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN

Jan 08, 2026

Jan 08, 2026

Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets - MyChesCo

Jan 08, 2026

Jan 06, 2026

Jefferies reiterates Buy rating on Aclaris Therapeutics stock at $7 price target - Investing.com Canada

Jan 06, 2026

Jan 06, 2026

Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans - MarketBeat

Jan 06, 2026

Jan 06, 2026

Aclaris Therapeutics Reports Positive Phase 1a Data For ATI-052 - Nasdaq

Jan 06, 2026

Jan 06, 2026

Aclaris advances ATI-052 after positive Phase 1a results - TipRanks

Jan 06, 2026

Jan 06, 2026

Aclaris Therapeutics Announces Positive Interim Results from Phase 1a Trial of ATI-052 - TradingView — Track All Markets

Jan 06, 2026

Jan 06, 2026

Aclaris reports positive results for anti-inflammatory drug ATI-052 By Investing.com - Investing.com Australia

Jan 06, 2026

Jan 06, 2026

ACRS: ATI-052 showed best-in-class potential in phase 1a, enabling rapid advancement to phase 1b trials - TradingView — Track All Markets

Jan 06, 2026

Jan 06, 2026

Aclaris Therapeutics Reports Positive Interim Results for ATI-052 Phase 1a Trials and Outlines Future Development Plans - Quiver Quantitative

Jan 06, 2026

Jan 06, 2026

New Aclaris antibody shows potential for 3‑month dosing in skin and asthma care - Stock Titan

Jan 06, 2026

Jan 05, 2026

What analysts say about Aclaris Therapeutics Inc 8AT stockStock Market Trends & Affordable Portfolio Trading - Early Times

Jan 05, 2026

Jan 05, 2026

Hair Loss Treatment Market Booming with Rapid Growth Through 2032 | Viviscal, Cipla Inc., Aclaris Therapeutics, Inc. - openPR.com

Jan 05, 2026

Jan 03, 2026

Three Bridge Wealth Advisors LLC Takes Position in Aclaris Therapeutics, Inc. $ACRS - MarketBeat

Jan 03, 2026

Jan 01, 2026

Why Aclaris Therapeutics Inc. stock remains undervaluedMoving Average Strategies & Exceptional Profit Trading - bollywoodhelpline.com

Jan 01, 2026

Dec 29, 2025

Aclaris Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN

Dec 29, 2025

Dec 29, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Dec 29, 2025

Dec 29, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Dec 29, 2025

Dec 28, 2025

What drives Aclaris Therapeutics Inc stock priceEarnings Forecast Updates & Big Profit Low Trading - earlytimes.in

Dec 28, 2025

Dec 24, 2025

Aclaris Joins Nasdaq Biotech Index, Marking Milestone for Clinical-Stage Firm - MyChesCo

Dec 24, 2025

Dec 22, 2025

Aclaris Therapeutics, Inc.(NasdaqGS: ACRS) added to NASDAQ Biotechnology Index - marketscreener.com

Dec 22, 2025

Dec 21, 2025

Gains Report: Is Aclaris Therapeutics Inc stock a good choice for value investorsJuly 2025 Opening Moves & AI Forecast for Swing Trade Picks - moha.gov.vn

Dec 21, 2025

Dec 20, 2025

Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - Улправда

Dec 20, 2025

Dec 20, 2025

Will Aclaris Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Breakouts & Risk Managed Investment Strategies - Улправда

Dec 20, 2025

Dec 20, 2025

Why Aclaris Therapeutics Inc. stock could see breakout soonJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда

Dec 20, 2025

Dec 20, 2025

Why Aclaris Therapeutics Inc. stock is rated strong buyJuly 2025 Gainers & Free Community Consensus Stock Picks - Улправда

Dec 20, 2025

Dec 20, 2025

How analysts rate Aclaris Therapeutics Inc. stock todayJuly 2025 Catalysts & Safe Capital Preservation Plans - Улправда

Dec 20, 2025

Dec 20, 2025

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - The Manila Times

Dec 20, 2025

Dec 20, 2025

Layoff Watch: Why Aclaris Therapeutics Inc. stock could rally in 2025 - Улправда

Dec 20, 2025

Dec 20, 2025

Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN

Dec 20, 2025

Dec 19, 2025

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index - Investing News Network

Dec 19, 2025

Dec 19, 2025

Aclaris Therapeutics Included in Nasdaq Biotechnology Index - marketscreener.com

Dec 19, 2025

Dec 19, 2025

Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025 - Quiver Quantitative

Dec 19, 2025

Dec 19, 2025

Is Aclaris Therapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Weekly Top Stock Performers List - Улправда

Dec 19, 2025

Dec 19, 2025

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up - simplywall.st

Dec 19, 2025